Abstract
The tripartite motif (TRIM) gene family is a highly conserved group of E3 ubiquitin ligase proteins that can establish substrate specificity for the ubiquitin-proteasome complex and also have proteasome-independent functions. While several family members were studied previously, it is relatively recent that over 80 genes, based on sequence homology, were grouped to establish the TRIM gene family. Functional studies of various TRIM genes linked these proteins to modulation of inflammatory responses showing that they can contribute to a wide variety of disease states including cardiovascular, neurological and musculoskeletal diseases, as well as various forms of cancer. Given the fundamental role of the ubiquitin-proteasome complex in protein turnover and the importance of this regulation in most aspects of cellular physiology, it is not surprising that TRIM proteins display a wide spectrum of functions in a variety of cellular processes. This broad range of function and the highly conserved primary amino acid sequence of family members, particularly in the canonical TRIM E3 ubiquitin ligase domain, complicates the development of therapeutics that specifically target these proteins. A more comprehensive understanding of the structure and function of TRIM proteins will help guide therapeutic development for a number of different diseases. This review summarizes the structural organization of TRIM proteins, their domain architecture, common and unique post-translational modifications within the family, and potential binding partners and targets. Further discussion is provided on efforts to target TRIM proteins as therapeutic agents and how our increasing understanding of the nature of TRIM proteins can guide discovery of other therapeutics in the future.
Original language | English |
---|---|
Pages (from-to) | 12-25 |
Number of pages | 14 |
Journal | Pharmacology and Therapeutics |
Volume | 185 |
DOIs | |
State | Published - May 2018 |
Bibliographical note
Publisher Copyright:© 2017 Elsevier Inc.
Funding
Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases MDA255597 of the National Institutes of Health under Award Number R01-AR063084 to NW. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support was provided by the Muscular Dystrophy Association (NW), the Internal Muscle Health and Neuromuscular Disorders Program (LG, SB) and the American Heart Association Postdoctoral Fellowship ( 14POST19990020 , LG).
Funders | Funder number |
---|---|
Internal Muscle Health and Neuromuscular Disorders Program | |
National Institutes of Health (NIH) | |
National Institute of Arthritis and Musculoskeletal and Skin Diseases | R01AR063084, MDA255597 |
American the American Heart Association | 14POST19990020 |
Muscular Dystrophy Association |
Keywords
- Cancer
- Drugs
- Inflammation
- Protein therapy
- Protein-protein interactions
- RING domain
- TRIM proteins
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)